Related references
Note: Only part of the references are listed.Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing
Meixian Jin et al.
STEM CELL RESEARCH & THERAPY (2021)
Gastrointestinal stromal tumours
Jean-Yves Blay et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Mitochondria as multifaceted regulators of cell death
Florian J. Bock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction
Xuequn Zhang et al.
HEPATOLOGY INTERNATIONAL (2020)
Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension
Jorie Versmissen et al.
CARDIOVASCULAR RESEARCH (2019)
The multiple mechanisms that regulate p53 activity and cell fate
Antonina Hafner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models
Giovanni Luca Gravina et al.
CANCERS (2019)
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma
Fangmin Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
EphA2 phosphorylation at Ser897 by the Cdk1/MEK/ERK/RSK pathway regulates M-phase progression via maintenance of cortical rigidity
Yuichiro Kaibori et al.
FASEB JOURNAL (2019)
Schisandra fruits for the management of drug-induced liver injury in China: A review
Peili Zhu et al.
PHYTOMEDICINE (2019)
Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines
Cecile Mingard et al.
JOURNAL OF APPLIED TOXICOLOGY (2018)
Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib
Man Tong et al.
JOURNAL OF HEPATOLOGY (2018)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2018)
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells
Franziska Paech et al.
TOXICOLOGY (2018)
p53 attenuates acetaminophen-induced hepatotoxicity by regulating drug-metabolizing enzymes and transporter expression
Jiahong Sun et al.
CELL DEATH & DISEASE (2018)
HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport
Peihua Luo et al.
AUTOPHAGY (2018)
Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of rapamycin
Hongbo Shi et al.
SCIENTIFIC REPORTS (2018)
LIVER CANCER Regorafenib - a new RESORCE in HCC
David Killock
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells
Jai-Jen Tsai et al.
ONCOLOGY REPORTS (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression
Yue Zhou et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2017)
p53 stability is regulated by diverse deubiquitinating enzymes
Seul-Ki Kwon et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
EphA2 Expression Regulates Inflammation and Fibroproliferative Remodeling in Atherosclerosis
Alexandra C. Finney et al.
CIRCULATION (2017)
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
Igho J. Onakpoya et al.
BMC MEDICINE (2016)
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain et al.
CANCER TREATMENT REVIEWS (2016)
Regorafenib induced severe toxic hepatitis: characterization and discussion
Anne Sacre et al.
LIVER INTERNATIONAL (2016)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Wei-Tien Tai et al.
CLINICAL CANCER RESEARCH (2014)
Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen et al.
CLINICAL CANCER RESEARCH (2014)
Drug-Induced Liver Injury and Drug Development: Industry Perspective
Arie Regev
SEMINARS IN LIVER DISEASE (2014)
EphA2 and Src regulate equatorial cell morphogenesis during lens development
Catherine Cheng et al.
DEVELOPMENT (2013)
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Rashmi R. Shah et al.
DRUG SAFETY (2013)
Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis
Xiang-Dan Cui et al.
HEPATOLOGY (2013)
Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease
Zoltan Derdak et al.
JOURNAL OF HEPATOLOGY (2013)
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease
Rui E. Castro et al.
JOURNAL OF HEPATOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Evidence That the EphA2 Receptor Exacerbates Ischemic Brain Injury
John Thundyil et al.
PLOS ONE (2013)
Roles of EphA2 in Development and Disease
Jeong Eun Park et al.
GENES (2013)
Eph-A2 Promotes Permeability and Inflammatory Responses to Bleomycin-Induced Lung Injury
Todd C. Carpenter et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2012)
Regorafenib for cancer
Dirk Strumberg et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Axis of ageing: telomeres, p53 and mitochondria
Erguen Sahin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease
Zoltan Derdak et al.
JOURNAL OF HEPATOLOGY (2011)
p53-insensitive PUMA down-regulation is essential in the early phase of liver regeneration after partial hepatectomy in mice
Song Chen et al.
JOURNAL OF HEPATOLOGY (2010)
Massively regulated genes: the example of TP53
Monica Hollstein et al.
JOURNAL OF PATHOLOGY (2010)
EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt
Hui Miao et al.
CANCER CELL (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
Bicyclol: A Novel Drug for Treating Chronic Viral Hepatitis B and C
Geng Tao Liu
MEDICINAL CHEMISTRY (2009)
p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis
Joana D. Amaral et al.
TRENDS IN MOLECULAR MEDICINE (2009)
EPHA2 Is Associated with Age-Related Cortical Cataract in Mice and Humans
Gyungah Jun et al.
PLOS GENETICS (2009)
Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase
Wei Bin Fang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2
Yoshinori Abe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in hepatocytes -: Mdm2 is activated in response to inhibited Akt signaling
Maria Malmlof et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
EphA2 phosphorylates the cytoplasmic tail of claudin-4 and mediates paracellular permeability
M Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Pifithrin-alpha induced p53 inhibition does not affect liver regeneration after partial hepatectomy in mice
C Eipel et al.
JOURNAL OF HEPATOLOGY (2005)
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery
CN Landen et al.
CANCER RESEARCH (2005)
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers
C Hafner et al.
CLINICAL CHEMISTRY (2004)
Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity
M Jiang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2004)
EphA kinase activation regulates HGF-induced epithelial branching morphogenesis
H Miao et al.
JOURNAL OF CELL BIOLOGY (2003)
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
BHP Zhou et al.
NATURE CELL BIOLOGY (2001)
Share Paper
